A5056852049- Nonmelanoma Skin Cancer Studies
- Cutaneous Melanoma Detection and Management
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Skin Protection and Aging
- Colorectal Cancer Treatments and Studies
- Cutaneous lymphoproliferative disorders research
- Esophageal and GI Pathology
- Cancer and Skin Lesions
- Colorectal Cancer Surgical Treatments
- Hernia repair and management
- Lung Cancer Research Studies
- Manufacturing Process and Optimization
- Acne and Rosacea Treatments and Effects
- Gastrointestinal disorders and treatments
- Metastasis and carcinoma case studies
- Breast Cancer Treatment Studies
- Gastrointestinal Tumor Research and Treatment
- Pancreatitis Pathology and Treatment
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
Istituto Dermopatico dell'Immacolata
2017-2025
Azienda Ospedaliera S.Maria
2024-2025
Institut Curie
2016-2024
Santa Maria Nuova Hospital
2012-2023
Swiss Group For Clinical Cancer Research
2023
Inserm
2022
Université Paris-Saclay
2022
University of Verona
1990-2021
Agostino Gemelli University Polyclinic
2020-2021
The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated platinum treatment sensitivity.To compare 6 cycles paclitaxel plus carboplatin (PCb) a standard-dose regimen 3 cyclophosphamide, epirubicin, fluorouracil followed by docetaxel (CEF-T).This phase randomized clinical trial was conducted at 9 centers hospitals China. Between July 1, 2011, April...
Immune checkpoint inhibitors (ICIs) have been demonstrated to improve overall survival (OS) in several tumor types. Durable responses reported with these agents patients melanoma and lung cancer. We aimed quantify the proportion of who experience durable on ICIs compare it other drug classes.We retrieved published phase III randomized trials that included at least one ICI arm recurrent and/or metastatic setting. A response treatment was defined as a progression-free exceeded three times...
•Final safety and efficacy results from PERUSE with ∼6 years' median follow-up are consistent CLEOPATRA results.•Results provide reassurance that paclitaxel is a valid alternative to docetaxel first-line pertuzumab trastuzumab.•In exploratory analyses, presence of both visceral disease prior trastuzumab identified subgroup worse PFS. BackgroundThe phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination pertuzumab, as standard therapy for...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Final overall survival (OS) SOPHIA (ClinicalTrials.gov identifier: NCT02492711 ), a study of margetuximab versus...
Anastomotic leakage is a severe complication in gastric surgery and it associated with high rate of mortality. Conservative treatment sometimes not sufficient to stem the leakages and, even when sufficient, takes long time. The present study describes first experience anastomotic endoscopic clipping.From May 1995 December 1996, seven patients postoperative after were prospectively treated our Endoscopy Service. Metallic endoclips (MD 850, Olympus Corp., Tokyo, Japan) prongs 12 mm 6 wide...
Summary Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral inhibitor, an expansion cohort patients with adenoid cystic carcinoma (ACC) who received dose-escalation-recommended 2 dose (RP2D), established previously (Massard C, et al., Annals Oncol 2018, 29:1911–17). Methods Patients advanced or metastatic cancer, measurable disease, ECOG-PS ≤1,...
Abstract Background Following the PALOMA-3 study results, combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, selective estrogen receptor degrader, has become standard therapy in women receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). Palbociclib been shown to increase progression-free survival (PFS) overall but no predictive biomarker palbociclib efficacy validated so far. We thus evaluated whether early changes circulating tumor DNA (ctDNA) levels...
The morbidity and mortality rates associated with acute cholecystitis are higher in the elderly. This study reports results of treatment elderly emergency ultrasonographically guided percutaneous cholecystostomy followed by elective cholecystectomy after endoscopic any common bile duct stones diagnosed cholangiography.From January 1989 to December 1998, 92 patients aged over 70 years were treated for gallstone cholecystitis. A group 84 ultrasonographic signs severe or an American Society...
Significance ΔNp63 is a master regulator of skin homeostasis since it finely controls keratinocyte differentiation and proliferation. Here, we provide cellular molecular evidence demonstrating the functional role interactor, R-loop–resolving enzyme Senataxin (SETX), in fine-tuning differentiation. We found that SETX physically binds p63 DNA–binding motif present two early epidermal genes, Keratin 1 (KRT1) ZNF750, facilitating R-loop removal over their 3′ ends thus allowing efficient...
Tattooing is a widespread practice among the population, particularly young people. With increased popularity of tattoos, there have also been several reports acute and chronic adverse events after tattooing. Malignant melanoma cases arising from tattoos increasingly described; however, no clear relationship between this tumorigenesis. We present case two synchronous melanomas (one located on decorative tattoo) update literature.